or Try an Advanced Search...

    Milatuzumab Stocks List

    Symbol Grade Name % Change
    STRO F Sutro Biopharma, Inc. -5.24
    BNOX F Bionomics Limited -1.56
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Antineoplastic Drugs Cancer Cancer Treatment Clinical Medicine Alzheimer's Disease Antibodies Anxiolytics Autoimmune Disorders Biology Biopharmaceutical Camidanlumab Tesirine Central Nervous System Disorders Cognitive Impairment Drug Discovery Drugs Endometrial Cancer Hodgkin Lymphoma Immune Disorders Immunogen Immunology

    Related ETFs - A few ETFs which own one or more of the above listed Milatuzumab stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.12
    QQQS C Invesco NASDAQ Future Gen 200 ETF 0.43
    SBIO C ALPS Medical Breakthroughs ETF 0.17
    IWC B iShares Microcap ETF 0.06
    FESM B Fidelity Enhanced Small Cap ETF 0.05
    View all Milatuzumab ETFs...
    Compare ETFs
    Compare CNCR to FESM Compare QQQS to IWC Compare SBIO to FESM

        Milatuzumab Stocks Recent News

        Date Stock Title
        Nov 18 BNOX Bionomics files for $100M mixed securities shelf
        Nov 18 STRO Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
        Nov 15 STRO Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
        Related Industries: Biotechnology
        Related Stock Lists: Antineoplastic Drugs Cancer Cancer Treatment Clinical Medicine Alzheimer's Disease Antibodies Anxiolytics Autoimmune Disorders Biology Biopharmaceutical Camidanlumab Tesirine Central Nervous System Disorders Cognitive Impairment Drug Discovery Drugs Endometrial Cancer Hodgkin Lymphoma Immune Disorders Immunogen Immunology
        Milatuzumab

        Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
        Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).

        More about Milatuzumab
        Browse All Tags